Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + floxuridine + dexamethasone
- Development stage
- Unknown
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Small Molecules
- Administration
- Intravenous, Intra-arterial
01
Overview
This combination therapy is being investigated by Memorial Sloan Kettering Cancer Center (MSKCC) as an adjuvant treatment for patients with intrahepatic cholangiocarcinoma who have undergone surgical resection. The regimen consists of systemic (intravenous) gemcitabine combined with hepatic arterial infusion (HAI) of floxuridine and dexamethasone. Gemcitabine is a nucleoside analog that inhibits DNA synthesis by replacing cytidine during DNA replication and inhibiting ribonucleotide reductase. Floxuridine, a pyrimidine analog, is delivered directly to the liver via an implanted pump to achieve high local concentrations with minimal systemic toxicity. Dexamethasone is added to the HAI pump to reduce the risk of biliary toxicity, specifically sclerosing cholangitis, which is a known side effect of regional floxuridine administration. This multimodal approach aims to reduce the high rate of recurrence following surgical resection of liver-confined bile duct cancers.
- Brand names
- GemzarFUDRDecadron
- Other names
- Adjuvant HAI Floxuridine and GemcitabineHAI Floxuridine + Systemic Gemcitabine
02
Targets
TS (Thymidylate synthase)GR (Glucocorticoid receptor)RNR (Ribonucleotide reductase)DNA
Beyond the preview
Go deeper on gemcitabine + floxuridine + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + floxuridine + dexamethasone.